celecoxib has been researched along with Canine Diseases in 6 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Celecoxib, a selective COX-2 inhibitor, inhibits cell growth of various types of human cancer including malignant melanoma." | 7.80 | Antitumor effects of celecoxib in COX-2 expressing and non-expressing canine melanoma cell lines. ( Ahn, JO; Coh, YR; Han, SM; Lee, HW; Rebhun, RB; Seo, KW; Youn, HY, 2014) |
| "9% bromfenac (Xibrom™) or a celecoxib-impregnated intraocular lens (celecoxib-IOL) compared with 1% prednisolone acetate (PA) in controlling postoperative inflammation and posterior capsule opacification (PCO)." | 3.81 | Efficacy of COX-2 inhibitors in controlling inflammation and capsular opacification after phacoemulsification cataract removal. ( Brookshire, HL; English, RV; Gift, BW; Gilger, BC; Nadelstein, B; Weigt, AK, 2015) |
| " Celecoxib, a selective COX-2 inhibitor, inhibits cell growth of various types of human cancer including malignant melanoma." | 3.80 | Antitumor effects of celecoxib in COX-2 expressing and non-expressing canine melanoma cell lines. ( Ahn, JO; Coh, YR; Han, SM; Lee, HW; Rebhun, RB; Seo, KW; Youn, HY, 2014) |
| "Celecoxib plays antitumor roles via multiple mechanisms in a variety of human cancers." | 1.42 | Celecoxib exerts antitumor effects in canine mammary tumor cells via COX‑2‑independent mechanisms. ( Asano, R; Kawashima, M; Murata, K; Saito, T; Tamura, D, 2015) |
| "Both rofecoxib and celecoxib were effective at inhibiting PCO formation in our ex vivo model." | 1.34 | Prevention of posterior capsular opacification through cyclooxygenase-2 inhibition. ( Barden, CA; Chandler, HL; Colitz, CM; Kusewitt, DF; Lu, P, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brookshire, HL | 1 |
| English, RV | 1 |
| Nadelstein, B | 1 |
| Weigt, AK | 1 |
| Gift, BW | 1 |
| Gilger, BC | 1 |
| Seo, KW | 1 |
| Coh, YR | 1 |
| Rebhun, RB | 1 |
| Ahn, JO | 1 |
| Han, SM | 1 |
| Lee, HW | 1 |
| Youn, HY | 1 |
| Tamura, D | 1 |
| Saito, T | 1 |
| Murata, K | 1 |
| Kawashima, M | 1 |
| Asano, R | 1 |
| Pawlak, A | 1 |
| Ziolo, E | 1 |
| Kutkowska, J | 1 |
| Blazejczyk, A | 1 |
| Wietrzyk, J | 1 |
| Krupa, A | 1 |
| Hildebrand, W | 1 |
| Dziegiel, P | 1 |
| Dzimira, S | 1 |
| Obminska-Mrukowicz, B | 1 |
| Strzadala, L | 1 |
| Rapak, A | 1 |
| Lane, R | 1 |
| Chandler, HL | 1 |
| Barden, CA | 1 |
| Lu, P | 1 |
| Kusewitt, DF | 1 |
| Colitz, CM | 1 |
6 other studies available for celecoxib and Canine Diseases
| Article | Year |
|---|---|
Efficacy of COX-2 inhibitors in controlling inflammation and capsular opacification after phacoemulsification cataract removal.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzophenones; Bromobenzenes; Celecoxib; Cyclooxyg | 2015 |
Antitumor effects of celecoxib in COX-2 expressing and non-expressing canine melanoma cell lines.
Topics: Animals; Blotting, Western; Celecoxib; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; | 2014 |
Celecoxib exerts antitumor effects in canine mammary tumor cells via COX‑2‑independent mechanisms.
Topics: Animals; Antineoplastic Agents; Celecoxib; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinases; | 2015 |
A novel canine B-cell leukaemia cell line. Establishment, characterisation and sensitivity to chemotherapeutics.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Celecoxib; Cell Line, Tumor; D | 2017 |
A protocol for labrador retrievers?
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents, Hormonal; Celecoxib; Cyclooxygenase 2 Inhibit | 2009 |
Prevention of posterior capsular opacification through cyclooxygenase-2 inhibition.
Topics: Animals; Apoptosis; Biomarkers; Cataract; Celecoxib; Cell Differentiation; Cell Movement; Cell Proli | 2007 |